Seelos Therapeutics, Inc. Common Stock
SEEL
SEEL was delisted on the 15th of October, 2024.
14 hedge funds and large institutions have $5.86M invested in Seelos Therapeutics, Inc. Common Stock in 2019 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 6 increasing their positions, reducing their positions, and 4 closing their positions.
100% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 4
60% more capital invested
Capital invested by funds: $3.66M → $5.86M (+$2.19M)
40% more funds holding
Funds holding: 10 → 14 (+4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UIC
Uniplan Investment Counsel
Milwaukee,
Wisconsin
|
+$1.89M |
| 2 |
Renaissance Technologies
New York
|
+$1.24M |
| 3 |
PSC
Piper Sandler & Co
Minneapolis,
Minnesota
|
+$453K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$326K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$316K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$213K |
| 2 |
Jane Street
New York
|
-$168K |
| 3 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$54K |
| 4 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$10.5K |
| 5 |
FDCDDQ
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
|
-$77 |
SEEL Hedge Fund Activity: Q2 2019 in Review
14 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Seelos Therapeutics, Inc. Common Stock (SEEL) for Q2 2019, worth a combined $5.86M — up 60% from $3.66M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new SEEL positions and 4 closed out — a net gain of 4 holders — while 6 added to existing stakes and 0 trimmed.
The largest buyer was Uniplan Investment Counsel, opening a new position worth an estimated $1.89M. The largest seller was Millennium Management, exiting entirely with an estimated $213K sold.
- 14 institutional investors held Seelos Therapeutics, Inc. Common Stock (SEEL) as of Q2 2019, up from 10 in Q1 2019.
- Funds reported $5.86M of Seelos Therapeutics, Inc. Common Stock stock for Q2 2019, up 60% quarter-over-quarter.
- 8 funds opened new Seelos Therapeutics, Inc. Common Stock positions in Q2 2019 and 4 closed out, a net change of +4 holders.
- The largest Seelos Therapeutics, Inc. Common Stock buyer in Q2 2019 was Uniplan Investment Counsel, an estimated $1.89M added.
- The largest Seelos Therapeutics, Inc. Common Stock seller in Q2 2019 was Millennium Management, an estimated $213K sold.
Based on aggregated 13F filings for Q2 2019.